AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment - CNBC
Source: CNBC ·
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment CNBCAstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types AstraZenecaFierce Pharma Asia—AZ’s $2B bet on ivonescimab; Novo buys Hengrui GLP-1; Merck doubles down on KRAS…